Avenue Therapeutics (ATXI) Misses Q2 EPS by 39c

Avenue Therapeutics (NASDAQ: ATXI) reported Q2 EPS of ($0.52), $0.39 worse than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Arrive AI and DXC Technology partner to bring delivery tech to factories
• Premarket movers: Xenon sinks on trial pause, Netflix hit by downgrade